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New Technology Add- On Payment 
(NTAP) for Viz LVO: a win for stroke care
Ameer E Hassan   
INTRODUCTION
The Centers for Medicare and Medicaid 
Services (CMS) recently granted a New 
Technology Add- on Payment (NTAP) for 
Viz ContaCT (Viz LVO) by  Viz. ai, Inc, an 
applied artificial intelligence healthcare 
company.1 This is the first time CMS has 
reimbursed an artificial intelligence (AI)- 
based software using this designation. It 
applies to  Viz. ai’s acute ischemic stroke 
product, Viz LVO, officially known as Viz 
ContaCT, under which the ICD-10 Proce-
dure Coding System (ICD-10- PCS) proce-
dure code 4A03×5D was established. 
Viz ContaCT is an AI- based system that 
creates a parallel alert system whenever it 
detects a large vessel occlusion (LVO) on 
a computed tomography angiogram. The 
images are viewable on a mobile appli-
cation which combines HIPAA (Health 
Insurance Portability and Accountability 
Act)- compliant group messaging function-
ality with a mobile PACS Viewer. Users can 
view the images, make triage decisions, 
and communicate with other members of 
the care team through chat functionality.
Beyond the specific designation, this 
decision may have far- reaching implica-
tions for stroke care and for reimburse-
ment of AI- enabled applications.
What is NTAP?
At a national level, reimbursement is how 
health care incentivizes helping patients. 
Medicare pays for a patient’s hospital 
stay according to the Inpatient Prospec-
tive Payment System (IPPS) under a single 
bundled payment, which includes all 
costs. These payments are captured under 
the Medicare Severity Diagnosis- Related 
Group (MS- DRG) system. While the 
MS- DRG rates are updated annually, the 
payments are based on Medicare claims 
data accrued over a 2 to 3 year period. 
The result is that payments lag behind true 
costs, particularly for care using new and 
expensive technologies.2
Introduced in 2001, the CMS NTAP 
program was created by Congress to help 
close this gap and support timely access 
to innovative therapies for the Medicare 
population. For technologies accepted 
under this program, CMS provides an 
additional payment to hospitals above 
the standard MS- DRG payment amount. 
There is an application, review, and 
approval process for the NTAP program.
There are three criteria for NTAP:
 ► Newness—the technology must be 
novel, that is, <3 years old. Typically 
this excludes Food and Drug Admin-
istration (FDA) 510 k clearances, as 
by definition, these are predicated on 
another technology
 ► Cost—the technology is not 
adequately covered under the existing 
MS- DRG
 ► Substantial clinical improvement—the 
technology must prove to CMS that it 
provides a substantial clinical advan-
tage over other available technologies, 
typically in the form of improved 
patient outcomes.
NTAPs are granted based on evidence 
submitted with respect to specific prod-
ucts. Other AI companies can submit an 
application to CMS demonstrating they 
also meet the above criteria, for consider-
ation in a future IPPS NTAP.3
How the  Viz. ai NTAP works
In 2019, CMS revised its rules around 
reimbursement using the NTAP program, 
agreeing with concerns that capping 
the payment at the 50% rate may not 
adequately support healthcare inno-
vations. In response, CMS increased 
payment to 65% of the lesser of (1) the 
cost of the new medical service or tech-
nology or (2) the amount by which the 
costs of the case exceed the standard DRG 
payment.4 For the  Viz. ai NTAP code, the 
additional payment is capped at $1040.
To qualify, a patient must be a Medi-
care patient with a suspected stroke, 
and the estimated cost must exceed the 
Medicare reimbursement. As the name 
suggests, the payment is added on to 
the DRG payment to the hospital for a 
qualifying patient, so only applies if the 
patient is admitted. In my institution, 
Medicare patients account for approx-
imately 51% of our code strokes, and 
nationwide approximately 45% of these 
patients have an estimated cost greater 
than the DRG payment.5 For these 
patients, when the hospital uses Viz LVO 
the NTAP will help to defray costs with 
an additional payment, up to $1040.
Why this is a big deal for stroke
Given the current revenue climate, a $1040 
reimbursement per patient may seem high. 
In approving NTAP for Viz LVO, CMS 
recognized the clinical benefit of Viz LVO 
in the management of patients admitted 
with stroke. Thrombectomy has been 
proven to be a highly effective treatment 
for acute ischemic stroke, and we know 
that patients do significantly better the 
sooner they are treated.6 It has been esti-
mated that in each minute of an ongoing 
stroke, 1.9 million neurons, 14 billion 
synapses, and 12 km (7.5 miles) of myelin-
ated fibers are destroyed and that the 
ischemic brain loses neurons at an hourly 
rate equivalent to 3.6 years of normal 
aging.7 8 Data from the Highly Effective 
Reperfusion Evaluated in Multiple Endo-
vascular Stroke Trials (HERMES) collab-
orative suggests that every minute delay 
results in a loss of 4 days of disability- free 
life.9 Clearly, delays in stroke care result 
in significant negative outcomes both for 
patients and for the financial well- being of 
the healthcare system.
Cost- benefit analysis of thrombec-
tomy yields similarly striking results: 
achieving expanded treatment in cere-
bral ischemia 3 (eTICI 3) over eTICI 2b 
reperfusion resulted on average in 1.31 
incremental quality- adjusted life- years 
(QALYs) as well as healthcare and soci-
etal cost savings of $10 327 and $20 224 
per patient, respectively. An estimated 
$21 million and $36.8 million for the US 
healthcare system and society, respectively, 
could be saved by a 10% increase in the 
eTICI 2/3 reperfusion rate of all endovas-
cular thrombectomy- treated patients with 
stroke.10
The median loss in net monetary benefit 
of thrombectomy per minute was calcu-
lated to be $1059, and saving 10 min 
on average across the USA would save 
$249 million annually.9 Implementation 
of Viz LVO has been demonstrated to save 
66 min on average,11 suggesting a signifi-
cant return on investment for CMS.
The intent of the NTAP program is 
to encourage early adoption of new and 
clinically effective technology. The reim-
bursement, however, may also help to 
avoid perverse incentives in the healthcare 
system, in which clinically appropriate 
transfers to comprehensive stroke centers 
may be discouraged by either the receiving 
or sending facilities, due to issues of 
avoiding the cost of sicker patients or 
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retaining the reimbursement of funded 
patients.12
We have made great progress in our 
ability to treat stroke and change lives. 
Evidence of health benefits, however, do 
not necessarily translate into evidence 
of financial feasibility, and healthcare 
systems may defer purchase of potentially 
life- saving and cost- saving products until 
the financial concerns have been allevi-
ated. This decision represents a move by 
CMS to remove some of those barriers.
Why this is a big deal for health care
CMS has previously proposed reimburse-
ment for use of AI- enabled technology—
specifically automated retinal imaging—in 
its 2021 Medicare physician fee schedule 
proposed rule.13 This reimbursement 
model addresses diagnostic applications 
that perform functions analogous to those 
otherwise performed by physicians, but 
it is insufficient for novel uses, such as 
parallel processing and triage.
CMS grappled with several of these 
new concepts in its process of approving 
Viz ContaCT for NTAP.1 It had to deter-
mine how to define cost for an application 
with a subscription model—a common 
payment model for software, but not for 
physical tools. It had to understand how 
it should consider the “novelty” of tech-
nology given AI’s capacity for learning and 
improvement. It also had to consider the 
value of technology to improve workflow, 
going beyond the traditional paradigms 
of straightforward diagnosis and treat-
ment. Although healthcare AI tools and 
companies have been in the headlines over 
the past few years, healthcare has been 
slower to adopt AI- powered applications 
than other industries. Initial excitement 
over proofs- of- concept and early progress 
can quickly die without a viable financial 
model to support further development 
and deployment.
NTAP itself is unlikely to represent a 
comprehensive solution for large- scale 
AI market success, given the inherent 
limitations. It is a time- limited decision 
which is reviewed annually and expires 
after 3 years, at which point the cost of 
the technology may or may not be incor-
porated into the Medicare reimbursement 
calculation, and the cost- benefit consid-
erations will change. The NTAP decision 
specifies a single product as qualifying for 
the additional payment, and CMS has to 
determine whether this applies to other 
products or not; to date, no other prod-
ucts have been deemed eligible by CMS. 
Additionally, the NTAP requirement of 
demonstrating novelty, high cost, and 
improved clinical outcome represents a 
barrier to acquire or even to attempt to 
acquire such a designation.
That said, the fact that CMS has begun 
to answer some of the questions of how 
AI- powered tools can be incorporated into 
reimbursement structures has illuminated 
a possible pathway to a realistic healthcare 
market for this technology.
CONCLUSION/TAKEAWAYS
In health care, doing the right thing for 
patients unfortunately is not enough. In 
order for new techniques, tools, and tech-
nology to be accepted and spread, they 
have to be incentivized. This is a land-
mark decision, as it marks the beginning 
of figuring out how we incentivize tools 
that target what is often the most chal-
lenging part of health care—the workflow 
issues that result from fragmented and 
unoptimized systems. It’s a start to under-
standing how we might pay for advanced 
technology like AI, so we can accelerate 
adopting increasingly effective tools into 
our practices. More specifically, it’s a win 
for stroke care, and the patients who will 
benefit from the treatment that we can 
provide, now more efficiently.
Time will tell, but we may look back 
and decide that this was the inflection 
point, the beginning of a new age in accep-
tance of this technology into the health-
care mainstream.
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